The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Pancreatic Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Pancreatic Neoplasms


Psychiatry related information on Pancreatic Neoplasms


High impact information on Pancreatic Neoplasms


Chemical compound and disease context of Pancreatic Neoplasms


Biological context of Pancreatic Neoplasms


Anatomical context of Pancreatic Neoplasms


Gene context of Pancreatic Neoplasms


Analytical, diagnostic and therapeutic context of Pancreatic Neoplasms


  1. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. Lowenfels, A.B., Maisonneuve, P., DiMagno, E.P., Elitsur, Y., Gates, L.K., Perrault, J., Whitcomb, D.C. J. Natl. Cancer Inst. (1997) [Pubmed]
  2. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. Crawford, H.C., Scoggins, C.R., Washington, M.K., Matrisian, L.M., Leach, S.D. J. Clin. Invest. (2002) [Pubmed]
  3. Role of trypsin/creatinine clearance ratio in the differential diagnosis of chronic pancreatic disease. Farini, R., Fabris, C., del Favero, G., Bonvicini, P., de' Best, T., Piccoli, A., Baccaglini, U., Plebani, M., Pedrazzoli, S., Kind, R., Ceriotti, G., Naccarato, R. Gastroenterology (1981) [Pubmed]
  4. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., Inoue, M., Nakamura, H. Gastroenterology (2002) [Pubmed]
  5. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Yamamoto, M., Davydova, J., Wang, M., Siegal, G.P., Krasnykh, V., Vickers, S.M., Curiel, D.T. Gastroenterology (2003) [Pubmed]
  6. Pancreatic cancer, blood glucose and beverage consumption. Hiatt, R.A., Klatsky, A.L., Armstrong, M.A. Int. J. Cancer (1988) [Pubmed]
  7. Risk factors for pancreatic cancer: case-control study. Hassan, M.M., Bondy, M.L., Wolff, R.A., Abbruzzese, J.L., Vauthey, J.N., Pisters, P.W., Evans, D.B., Khan, R., Chou, T.H., Lenzi, R., Jiao, L., Li, D. Am. J. Gastroenterol. (2007) [Pubmed]
  8. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Ozçelik, H., Schmocker, B., Di Nicola, N., Shi, X.H., Langer, B., Moore, M., Taylor, B.R., Narod, S.A., Darlington, G., Andrulis, I.L., Gallinger, S., Redston, M. Nat. Genet. (1997) [Pubmed]
  9. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Eppert, K., Scherer, S.W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.C., Bapat, B., Gallinger, S., Andrulis, I.L., Thomsen, G.H., Wrana, J.L., Attisano, L. Cell (1996) [Pubmed]
  10. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. Goldstein, A.M., Fraser, M.C., Struewing, J.P., Hussussian, C.J., Ranade, K., Zametkin, D.P., Fontaine, L.S., Organic, S.M., Dracopoli, N.C., Clark, W.H. N. Engl. J. Med. (1995) [Pubmed]
  11. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. Permert, J., Larsson, J., Westermark, G.T., Herrington, M.K., Christmanson, L., Pour, P.M., Westermark, P., Adrian, T.E. N. Engl. J. Med. (1994) [Pubmed]
  12. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Xing, H.R., Cordon-Cardo, C., Deng, X., Tong, W., Campodonico, L., Fuks, Z., Kolesnick, R. Nat. Med. (2003) [Pubmed]
  13. Abnormal glucose metabolism and pancreatic cancer mortality. Gapstur, S.M., Gann, P.H., Lowe, W., Liu, K., Colangelo, L., Dyer, A. JAMA (2000) [Pubmed]
  14. Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. Dougherty, J.B., Kelsen, D., Kemeny, N., Magill, G., Botet, J., Niedzwiecki, D. J. Natl. Cancer Inst. (1989) [Pubmed]
  15. Pancreatic cancer risk and nutrition-related methyl-group availability indicators in male smokers. Stolzenberg-Solomon, R.Z., Albanes, D., Nieto, F.J., Hartman, T.J., Tangrea, J.A., Rautalahti, M., Sehlub, J., Virtamo, J., Taylor, P.R. J. Natl. Cancer Inst. (1999) [Pubmed]
  16. Interaction of dietary fat and protein on pancreatic carcinogenesis in Syrian golden hamsters. Birt, D.F., Stepan, K.R., Pour, P.M. J. Natl. Cancer Inst. (1983) [Pubmed]
  17. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Phillips, P.A., Dudeja, V., McCarroll, J.A., Borja-Cacho, D., Dawra, R.K., Grizzle, W.E., Vickers, S.M., Saluja, A.K. Cancer Res. (2007) [Pubmed]
  18. Dietary glycemic load, added sugars, and carbohydrates as risk factors for pancreatic cancer: the Multiethnic Cohort Study. Nöthlings, U., Murphy, S.P., Wilkens, L.R., Henderson, B.E., Kolonel, L.N. Am. J. Clin. Nutr. (2007) [Pubmed]
  19. Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells. Diep, C.H., Munoz, R.M., Choudhary, A., Von Hoff, D.D., Han, H. Clin. Cancer Res. (2011) [Pubmed]
  20. Overexpression of ecdysoneless in pancreatic cancer and its role in oncogenesis by regulating glycolysis. Dey, P., Rachagani, S., Chakraborty, S., Singh, P.K., Zhao, X., Gurumurthy, C.B., Anderson, J.M., Lele, S., Hollingsworth, M.A., Band, V., Batra, S.K. Clin. Cancer Res. (2012) [Pubmed]
  21. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Engelke, C.G., Parsels, L.A., Qian, Y., Zhang, Q., Karnak, D., Robertson, J.R., Tanska, D.M., Wei, D., Davis, M.A., Parsels, J.D., Zhao, L., Greenson, J.K., Lawrence, T.S., Maybaum, J., Morgan, M.A. Clin. Cancer Res. (2013) [Pubmed]
  22. Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer. Li, L., Du, Y., Kong, X., Li, Z., Jia, Z., Cui, J., Gao, J., Wang, G., Xie, K. Clin. Cancer Res. (2013) [Pubmed]
  23. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. Thomas, A.M., Santarsiero, L.M., Lutz, E.R., Armstrong, T.D., Chen, Y.C., Huang, L.Q., Laheru, D.A., Goggins, M., Hruban, R.H., Jaffee, E.M. J. Exp. Med. (2004) [Pubmed]
  24. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. Kornmann, M., Arber, N., Korc, M. J. Clin. Invest. (1998) [Pubmed]
  25. BRCA2 germline mutations in familial pancreatic carcinoma. Hahn, S.A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J.A., Campra, D., Grützmann, R., Rehder, H., Rothmund, M., Schmiegel, W., Neoptolemos, J.P., Bartsch, D.K. J. Natl. Cancer Inst. (2003) [Pubmed]
  26. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. Duell, E.J., Holly, E.A., Bracci, P.M., Liu, M., Wiencke, J.K., Kelsey, K.T. J. Natl. Cancer Inst. (2002) [Pubmed]
  27. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Saur, D., Seidler, B., Schneider, G., Algül, H., Beck, R., Senekowitsch-Schmidtke, R., Schwaiger, M., Schmid, R.M. Gastroenterology (2005) [Pubmed]
  28. Aging changes of pancreatic isoamylases and the appearance of "old amylase" in the serum of patients with pancreatic pseudocysts. Warshaw, A.L., Lee, K.H. Gastroenterology (1980) [Pubmed]
  29. Overexpression of heparin-binding EGF-like growth factor in mouse pancreas results in fibrosis and epithelial metaplasia. Means, A.L., Ray, K.C., Singh, A.B., Washington, M.K., Whitehead, R.H., Harris, R.C., Wright, C.V., Coffey, R.J., Leach, S.D. Gastroenterology (2003) [Pubmed]
  30. Elevated serum ribonuclease in patients with pancreatic cancer. Reddi, K.K., Holland, J.F. Proc. Natl. Acad. Sci. U.S.A. (1976) [Pubmed]
  31. KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Guo, X., Friess, H., Graber, H.U., Kashiwagi, M., Zimmermann, A., Korc, M., Büchler, M.W. Cancer Res. (1996) [Pubmed]
  32. A human Mad protein acting as a BMP-regulated transcriptional activator. Liu, F., Hata, A., Baker, J.C., Doody, J., Cárcamo, J., Harland, R.M., Massagué, J. Nature (1996) [Pubmed]
  33. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. Goldstein, A.M., Struewing, J.P., Chidambaram, A., Fraser, M.C., Tucker, M.A. J. Natl. Cancer Inst. (2000) [Pubmed]
  34. Cancer Incidence in BRCA1 mutation carriers. Thompson, D., Easton, D.F. J. Natl. Cancer Inst. (2002) [Pubmed]
  35. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. von Marschall, Z., Cramer, T., Höcker, M., Burde, R., Plath, T., Schirner, M., Heidenreich, R., Breier, G., Riecken, E.O., Wiedenmann, B., Rosewicz, S. Gastroenterology (2000) [Pubmed]
  36. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Vitale, G., van Eijck, C.H., van Koetsveld Ing, P.M., Erdmann, J.I., Speel, E.J., van der Wansem Ing, K., Mooij, D.M., Colao, A., Lombardi, G., Croze, E., Lamberts, S.W., Hofland, L.J. Ann. Surg. (2007) [Pubmed]
  37. The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Whiteman, H.J., Weeks, M.E., Dowen, S.E., Barry, S., Timms, J.F., Lemoine, N.R., Crnogorac-Jurcevic, T. Cancer Res. (2007) [Pubmed]
  38. HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Kolb, S., Fritsch, R., Saur, D., Reichert, M., Schmid, R.M., Schneider, G. Cancer Res. (2007) [Pubmed]
  39. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Wu, M., Min, C., Wang, X., Yu, Z., Kirsch, K.H., Trackman, P.C., Sonenshein, G.E. Cancer Res. (2007) [Pubmed]
  40. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Li, L.S., Bey, E.A., Dong, Y., Meng, J., Patra, B., Yan, J., Xie, X.J., Brekken, R.A., Barnett, C.C., Bornmann, W.G., Gao, J., Boothman, D.A. Clin. Cancer Res. (2011) [Pubmed]
  41. KL1 Internal Repeat Mediates Klotho Tumor Suppressor Activities and Inhibits bFGF and IGF-I Signaling in Pancreatic Cancer. Abramovitz, L., Rubinek, T., Ligumsky, H., Bose, S., Barshack, I., Avivi, C., Kaufman, B., Wolf, I. Clin. Cancer Res. (2011) [Pubmed]
  42. ERCP meets C-K-ras: towards an improved diagnosis of pancreatic cancer. Pasricha, P.J. Gastroenterology (1996) [Pubmed]
  43. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Scholz, A., Heinze, S., Detjen, K.M., Peters, M., Welzel, M., Hauff, P., Schirner, M., Wiedenmann, B., Rosewicz, S. Gastroenterology (2003) [Pubmed]
  44. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Berthélemy, P., Bouisson, M., Escourrou, J., Vaysse, N., Rumeau, J.L., Pradayrol, L. Ann. Intern. Med. (1995) [Pubmed]
  45. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Redding, T.W., Schally, A.V. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  46. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Modrak, D.E., Cardillo, T.M., Newsome, G.A., Goldenberg, D.M., Gold, D.V. Cancer Res. (2004) [Pubmed]
WikiGenes - Universities